FlashFeed

Botox maker profits from "Ozempic face" trend as facial sagging drives demand

The aesthetics company behind Botox is reporting a business boost driven by the growing use of GLP-1 drugs like Ozempic, which can cause facial volume loss — a phenomenon dubbed "Ozempic face." As more patients experience sagging skin after weight loss, demand for cosmetic treatments such as fillers is rising. The company expects the GLP-1 trend to be a sustained long-term driver of its business.